天然产物研究与开发 ›› 2020, Vol. 32 ›› Issue (增刊1): 101-108.doi: 10.16333/j.1001-6880.2020.S.017

• 开发研究 • 上一篇    下一篇

芪苈强心胶囊治疗心肌梗死的网络药理学研究

于莉1,2,马石楠,2罗心霞2,汪珊2,胡恋2,周君阳2,王珏3,李世刚1*   

  1. 1三峡大学,宜昌 443002;2湖北医药学院胚胎干细胞研究湖北省重点实验室,湖北医药学院 十堰市太和医院(湖北医药学院附属医院);3湖北医药学院病理教研室 十堰 442000


  • 出版日期:2020-06-28 发布日期:2020-07-20
  • 基金资助:
    湖北医药学院自由探索基金(FDFR201803);广西科学技术厅项目(2018JJA140751)

Network pharmacology study on the mechanism of Qiliqiangxin capsule in treatment of myocardial infarction

YU Li1,2,MA Shi-nan2,LUO Xin-xia2,WANG Shan2,HU Lian2,ZHOU Jun-yang2,WANG Jue3,LI Shi-gang1*   

  1. 1China Three Gorges University,Yichang,443002,China;2Hubei Key Laboratory of Embryonic Stem Cell Research,Taihe Hospital,Hubei University of Medicine;3Department of Pathology,Hubei University of Medicine,Shiyan 442000,China
  • Online:2020-06-28 Published:2020-07-20

摘要: 本研究旨在应用网络药理学方法探讨芪苈强心胶囊治疗心肌梗死的作用机制。通过TCMSP数据库和Pubmed筛选芪苈强心胶囊中结构与生物活性明确的有效成分、对应的潜在靶点。运用Genecards、OMIM数据库搜集心肌梗死的相关靶点,Cytoscape软件构建“药物-成分-靶点-疾病”网络,STRING数据库绘制PPI网络,对关键靶点进行GO富集分析和KEGG通路富集分析。芪苈强心胶囊靶向心肌梗死的有效成分106个,包括槲皮素、山柰酚、毛蕊异黄酮等,可能通过靶向STAT3、AKT1、IL6等188个靶蛋白,调控TNF、IL-17、Th17细胞分化、Apoptosis在内的173条信号通路。综上,芪苈强心胶囊治疗心肌梗死的药理学机制可能是通过多成分、多靶点、多通路及多层次实现的,为进一步研究提供思路与依据。

关键词: 芪苈强心胶囊, 心肌梗死, 网络药理学, 作用机制

Abstract: To investigate the mechanism of Qiliqiangxin capsule in the treatment of myocardial infarction based on network pharmacology.TCMSP database and Pubmed was applied to screening active components and potential targets of the 11 traditional Chinese medicines.The myocardial infarction(MI)-related targets were collected from Genecards and OMIM database.Drug-component-target-disease network diagram was construbted by Cytoscape software.STRING database was used to draw PPI network.The gene ontology (GO) and KEGG pathway enrichment analysis were conducted for key targets..There are 106 active ingredients in Qiliqiangxin capsule,including quercetin,kaferferol and calycosin,which may regulate 173 signaling pathways including TNF,il-17 and Th17 cell differentiation and Apoptosis by targeting 188 target proteins such as STAT3,AKT1 and IL6.In conclusion,the pharmacological mechanism of Qiliqiangxin capsule in the treatment of myocardial infarction may be multi-components,multi-targets,multi-pathways and multi-level.This study will provide theoretical basis for Qiliqiangxin to treat myocardial infarction.

Key words: Qiliqiangxin capsule, myocardial infarction, network pharmacology, mechanism

中图分类号:  R96